^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CM355

    i
    Other names: CM355, ICP-B02
    Associations

    News

    Trials
    Company:
    InnoCare, Keymed Biosciences
    Drug class:
    CD20 inhibitor, CD3 agonist
    Related drugs:
    Associations

    News

    Trials
    almost3years
    A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) (clinicaltrials.gov)
    P1/2, N=184, Active, not recruiting, Beijing InnoCare Pharma Tech Co., Ltd.
    New P1/2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 expression
    |
    CM355